Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeu ADR (NQ: SMMT )

24.56 -1.66 (-6.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,134,174
Open 26.17
Bid (Size) 24.54 (9)
Ask (Size) 24.59 (3)
Prev. Close 26.22
Today's Range 23.96 - 26.67
52wk Range 1.640 - 33.89
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
There's a lot of hope for ivonescimab, but are investors being a bit too bullish? 
Via The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days. 
Via Investor's Business Daily

Performance

YTD
+830.30%
+830.30%
1 Month
+100.49%
+100.49%
3 Month
+209.32%
+209.32%
6 Month
+576.58%
+576.58%
1 Year
+1256.91%
+1256.91%

More News

Read More
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Via Benzinga
Here's Why Everyone's Talking About Summit Therapeutics
Via The Motley Fool
Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Here's How Much $100 Invested In Summit Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Summit Therapeutics Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
From Summit Therapeutics Inc.
Via Business Wire
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Via Benzinga
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
Via The Motley Fool
Why Summit Therapeutics Skyrocketed 123% This Week
Via The Motley Fool
Why Summit Therapeutics Stock Is Soaring Again Today
Via The Motley Fool
Signet Jewelers Posts Better-Than-Expected Earnings, Joins NETGEAR, Lovesac And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
Via Investor's Business Daily
Summit Therapeutics Surges on Trial Results: Time to Buy?
Via MarketBeat
Why Summit Therapeutics (SMMT) Stock Is Rising Today
Via Benzinga
Summit Therapeutics Raises $235 Million
From Summit Therapeutics Inc.
Via Business Wire
Is Summit Therapeutics a Buy Now?
Via The Motley Fool
Why Summit Therapeutics Rocketed Over 60% Today
Via The Motley Fool
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
Starbucks To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
Via Investor's Business Daily
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Via Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
From Summit Therapeutics Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.